Sacral Erector Spinae Plane Block for Catheter-Related Bladder Discomfort After HoLEP

November 12, 2026 updated by: Kadriye Dıvrak, Ankara Etlik City Hospital

Evaluation of the Effect of Bilateral Sacral Erector Spinae Plane Block on Postoperative Catheter-Related Bladder Discomfort in Patients Undergoing Holmium Laser Enucleation of the Prostate

Catheter-related bladder discomfort (CRBD) is common after holmium laser enucleation of the prostate (HoLEP). This single-center, randomized, controlled, assessor-blinded trial evaluates whether an ultrasound-guided bilateral sacral erector spinae plane (S-ESP) block performed before general anesthesia reduces the incidence of CRBD compared with general anesthesia alone in men aged 50 to 80 years undergoing elective HoLEP. The primary outcome is the incidence of CRBD at 1 hour after surgery.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Catheter-related bladder discomfort (CRBD) is a common and distressing postoperative symptom complex in male patients undergoing Holmium Laser Enucleation of the Prostate (HoLEP), characterized by a suprapubic burning sensation, an urge to void, and involuntary bladder spasms due to three-way urinary catheterization and continuous bladder irrigation. The sacral erector spinae plane (S-ESP) block is an ultrasound-guided interfascial plane block that targets the S2-S4 sacral nerve roots, which provide both somatic (via the pudendal nerve) and visceral parasympathetic (via pelvic splanchnic nerves) innervation to the lower urinary tract. While current evidence regarding the efficacy of the S-ESP block against a no-block control group in HoLEP surgery is limited, blocking these sacral pathways may effectively modulate afferent bladder stimuli.

A total of 100 male patients aged 50 to 80 years with ASA physical status I-III scheduled for elective HoLEP surgery under general anesthesia will be randomly assigned in a 1:1 ratio to either the S-ESP block group (Group S, n=50) or the standard care control group (Group G, n=50) using computer-generated randomization and sealed opaque envelopes.

Patients in Group S will be placed in the prone position approximately 30 minutes before surgery under standard monitoring. Using a convex ultrasound transducer (GE HealthCare C1-5 probe) in a longitudinal paramedian orientation at the S2 intermediate sacral crest level, a 22G 80-100 mm echogenic block needle will be advanced in-plane in a craniocaudal direction into the fascial plane between the erector spinae aponeurosis and the sacral crest. Following hydrodissection with 1-2 mL normal saline and negative aspiration, 20 mL of 0.25% bupivacaine will be injected on each side (total 40 mL, 100 mg; not exceeding the maximum safe dose of 2 mg/kg). Sensory blockade will be assessed 30 minutes after block completion via pinprick testing over the bilateral S2-S4 dermatomes.

Both groups will receive a standardized general anesthesia protocol: induction with IV fentanyl (1 mcg/kg), propofol (2-2.5 mg/kg), and rocuronium (0.3 mg/kg) to facilitate laryngeal mask airway (LMA) insertion, followed by maintenance with 1 MAC sevoflurane and titrated remifentanil infusion (0.05-0.2 mcg/kg/min). Approximately 30 minutes before the end of surgery, all patients will receive IV paracetamol (1 g) and IV tramadol (100 mg) for multimodal analgesia, followed by routine postoperative IV paracetamol (1 g twice daily).

An independent anesthesiologist blinded to group allocation will assess postoperative outcomes at 30 minutes and at 1, 2, 4, 6, 12, and 24 hours. If the Visual Analog Scale (VAS) pain score is ≥4, IV tramadol (1 mg/kg, up to 400 mg/day) will be administered as rescue analgesia. If the CRBD score is ≥2 after excluding mechanical catheter obstruction, rescue antispasmodic or antimuscarinic medication will be administered. Quality of recovery will be evaluated at 24 hours using the validated Turkish version of the 15-item Quality of Recovery scale (QoR-15T).

Study Type

Interventional

Enrollment (Estimated)

100

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

50 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • Male patients aged between 50 and 80 years
  • American Society of Anesthesiologists (ASA) physical status class I to III
  • Scheduled for elective Holmium Laser Enucleation of the Prostate (HoLEP) surgery under general anesthesia
  • Patients who agree to participate in the study and sign the written informed consent form

Exclusion Criteria:

  • Age under 50 years or over 80 years
  • ASA physical status class IV or higher
  • Known hypersensitivity or allergy to local anesthetics
  • History of chronic opioid use
  • Chronic pain syndrome
  • History of peripheral neuropathy, sacral neurological disease, or neurogenic bladder
  • Overactive bladder or prominent preoperative bladder irritation symptoms
  • History of previous prostate, bladder neck, or lower urinary tract surgery
  • Active urinary tract infection
  • Anticoagulant/antiplatelet use that contraindicates block administration according to current regional anesthesia guidelines, or clinically significant coagulopathy
  • Infection or severe dermatological lesion at the block application site
  • Severe renal failure (eGFR < 30 mL/min/1.73m2) or clinically significant hepatic failure
  • Cognitive impairment, communication difficulty, or psychiatric/neurological condition preventing postoperative assessments
  • Anticipated need for postoperative intensive care unit admission
  • Presence of a preoperative indwelling urinary catheter
  • Emergency surgery
  • Patient refusal or withdrawal of consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: S-ESPB Group

Ultrasound-guided bilateral sacral erector spinae plane block with 20 mL of 0.25% bupivacaine per side, performed about 30 minutes before surgery, followed by standardized general anesthesia.

Ultrasound-guided bilateral sacral erector spinae plane block with 20 mL of 0.25% bupivacaine per side, performed about 30 minutes before surgery, followed by standardized general anesthesia

Active Comparator: Standard Care Group

Standardized general anesthesia without any block or sham injection.

Standardized general anesthesia without any block.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of Catheter-Related Bladder Discomfort (CRBD) at Postoperative 1 Hour
Time Frame: 1 hour after surgery

CRBD is graded on a 4-point scale: 0 = none; 1 = mild (reported only on questioning); 2 = moderate (reported spontaneously, without behavioral responses); 3 = severe (reported spontaneously with behavioral responses such as strong verbal response, flailing limbs or attempts to remove the catheter). Incidence is the proportion of patients with a score of 1 or higher.

1 hour after surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of CRBD at other time points
Time Frame: 30 minutes and 2, 4, 6, 12 and 24 hours after surgery

Proportion of patients with CRBD score of 1 or higher

30 minutes and 2, 4, 6, 12 and 24 hours after surgery
Severity of CRBD
Time Frame: 30 minutes and 1, 2, 4, 6, 12 and 24 hours after surgery

CRBD severity will be graded on a 4-point ordinal scale from 0 (none) to 3 (severe). Moderate-to-severe CRBD is defined as a score ≥2.

30 minutes and 1, 2, 4, 6, 12 and 24 hours after surgery
Postoperative pain score
Time Frame: 30 minutes and 1, 2, 4, 6, 12 and 24 hours after surgery

Postoperative pain intensity will be assessed using a 10-cm Visual Analog Scale (VAS) ranging from 0 (no pain) to 10 (worst pain).

30 minutes and 1, 2, 4, 6, 12 and 24 hours after surgery
Intraoperative remifentanil consumption
Time Frame: Intraoperative period

Total amount of intraoperative remifentanil consumed, recorded in micrograms (mcg) and normalized to body weight and duration (mcg/kg/hour).

Intraoperative period
Total Postoperative Rescue Analgesic Consumption
Time Frame: First 24 hours after surgery

Total intravenous tramadol dose in milligrams

First 24 hours after surgery
Time to First Rescue Analgesic Request
Time Frame: First 24 hours after surgery

Minutes from end of surgery to first rescue tramadol dose

First 24 hours after surgery
Antispasmodic or antimuscarinic requirement
Time Frame: First 24 hours after surgery

Proportion of patients requiring additional antispasmodic or antimuscarinic medication for persistent moderate-to-severe CRBD (score ≥2)

First 24 hours after surgery
Incidence of Postoperative Nausea and Vomiting (PONV) and Other Adverse Events
Time Frame: First 24 hours after surgery

Number and percentage of participants experiencing postoperative nausea and vomiting (PONV) or any block- or anesthesia-related adverse events.

First 24 hours after surgery
Postoperative Quality of Recovery Score (QoR-15T)
Time Frame: At 24 hours after surgery

Quality of recovery will be evaluated using the validated Turkish version of the 15-item Quality of Recovery scale (QoR-15T). Total scores range from 0 to 150, with higher scores indicating better postoperative recovery quality.

At 24 hours after surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Director: Derya Ozkan, Prof., MD, Ankara Etlik City Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 19, 2026

Primary Completion (Estimated)

March 16, 2027

Study Completion (Estimated)

March 31, 2027

Study Registration Dates

First Submitted

November 12, 2026

First Submitted That Met QC Criteria

November 12, 2026

First Posted (Actual)

November 18, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 12, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • AEŞH-EK-2026-180

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

All personal data will be anonymized and individual participant data will not be made publicly available in accordance with institutional ethics committee approval.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.